Tag Archives: (MRK)

The 2028 Patent Cliff And Other Fairy Tale

I remember sitting in a conference room at Merck’s (MRK) Kenilworth headquarters back in 2014, watching their presentations on some experimental cancer drug called pembrolizumab. Half the analysts in the room were checking their phones. That drug became Keytruda, now pulling in $32 billion annually, and those same analysts are convinced the company’s about to […]

December 30, 2025

Mad Hedge Biotech and Healthcare Letter December 30, 2025 Fiat Lux   Featured Trade: (BIOTECH’S WATERLOO: THE STOCKS THAT CONQUERED AND THE ONES THAT DIDN’T) (IDXX), (CAH), (HCA), (COR), (MCK), (GILD), (JNJ), (LLY), (ISRG), (WBA), (MRK), (BMY), (MRNA), (BIIB), (ILMN)

Biotech’s Waterloo: The Stocks That Conquered And The Ones That Didn’t

Napoleon once said, “In victory, you deserve champagne. In defeat, you need it.” Healthcare investors popped both in 2025. While the sector at large looked like a casualty of macro shrapnel, a few names marched through the battlefield with earnings like artillery fire – and stock prices to match. The top-line view was grim: the […]

Climbing The Cliff In Reverse

A few months ago, I found myself sipping flat champagne on a Gulfstream out of Aspen, locked in one of those altitude-fueled biotech postmortems. On my left: a hedge fund manager freshly out of his biotech positions after a bruising year. On my right: a dermatologist who moonlights as a GLP‑1 evangelist. Regeneron (REGN) came […]

Accumulation You Can Taste

Remember that scene in The Big Short where everyone thinks Michael Burry’s lost his mind betting against housing? That’s exactly how I felt last week at a biotech conference in Boston when I suggested Merck (MRK) might be the most mispriced asset in big pharma. The room went dead quiet. One PM actually choked on […]